Asset
PERIPHERAL BLOOD STEM/PROGENITOR CELLS, AUTOLOGOUS, CD34+, G-CSF MOBILIZED
Lisata Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00300053 | phase2 | completed | 2006-04-01 | 2008-03-01 | Lisata Therapeutics, Inc. | ACT34-CMI -- Adult Autologous CD34+ Cells |
| NCT04522817 | phase1 | withdrawn | 2020-10-05 | 2021-05-01 | Lisata Therapeutics, Inc. | CLBS119 for Repair of COVID-19 Induced Pulmonary Damage |
| NCT04990427 | phase1 | completed | 2022-01-10 | 2023-01-26 | Lisata Therapeutics, Inc. | CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM) |
| NCT02501018 | phase2 | completed | 2017-11-01 | 2022-05-19 | Lisata Therapeutics, Inc. | Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI) |
FDA applications (0)
This company has no applications containing this asset.